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Abstract 
Introduction: Several studies have pointed to high rates of substance use disorders among 
female prisoners. The present study aimed to assess comorbidities of substance use disorders 
with other mental disorders in female prisoners at admission to the penal justice system.  
Methods: A sample of 150 female prisoners, consecutively admitted to the penal justice 
system in Berlin, Germany, were interviewed using the Mini International Neuropsychiatric 
Interview (MINI). The presence of borderline personality disorder was assessed using the 
Structured Clinical Interview II for DSM-IV. Prevalence rates and comorbidities were 
calculated as percentage values and 95% confidence intervals CI.  
Results: Ninety-three prisoners (62%; 95% CI: 54-70) had substance use disorders; n=49 
(33%; 95% CI: 24-42) had alcohol abuse/dependence; n=76 (51%; 95% CI: 43-59) had illicit 
drug abuse/dependence; n=53 (35%; 95% CI: 28-44) had opiate use disorders. In the group of 
inmates with substance use disorders, 84 (90%) had at least one other mental disorder; n=63 
(68%) had comorbid affective disorders, n=45 (49%) borderline or antisocial personality 
disorders and n=41 (44%) comorbid anxiety disorders.  
Conclusions: Female prisoners with addiction have high rates of comorbid mental disorders 
at admission to the penal justice system, ranging from affective to personality and anxiety 
disorders. Generic and robust interventions that can address different comorbid mental health 
problems in a flexible manner may be required to tackle wide spread addiction and improve 
mental health of female prisoners.  
 
 
Keywords: substance use disorders, comorbidity, mental disorders, female prison population, 
prevalence rates, admission study 
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Highlights 
• A majority of 62% of females have substance use disorders at admission to prison 
• Opiates are the most frequent substances of addiction in 35% of this population 
• Addictions are highly comorbid with affective, personality and anxiety disorders 
• Comorbidities do not differ between subgroups addicted to different substances 
• Interventions should be generic, robust and flexible to cover different disorders 
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Introduction 
The number of imprisoned women has been increasing faster than the number of male 
prisoners worldwide and it has been suggested that female prisoners may have specific health 
care needs [1,2]. Despite this, most of the research so far has been conducted in male 
prisoners [3]. Existing evidence suggests that female prisoners have comparatively higher 
rates of addiction than male prisoners [4-8]. However, prevalence estimates for female 
prisoners have only been reported from few countries so far [9]. Moreover, they showed 
important variations between 10-24% for alcohol abuse/dependence and 30-60% for drug 
abuse/dependence for the one-year prevalence rates in a previous review [9]. The variations 
may be due to cultural and legal contexts. Drug abuse/dependence in consecutively admitted 
female prisoners might have been increasing over time. Different studies from the US 
reported lifetime prevalence rates of 26% in 1988 [10] and 44% in 1996 [3]. More recent 
research from Australia showed that 62% of female prisoners had used illegal drugs in the six 
months prior to arrest without specifying whether criteria for abuse or dependence were 
fulfilled [11]. A study of newly committed female prisoners conducted in Ireland had reported 
48% prevalence of drug use disorders [12]. Heroine had been identified as the most frequent 
substance causing dependence in female prisoners in the UK [13,14]. However, the types of 
illegal drugs of addiction were frequently not further specified in previous research. In all, the 
prevalence rates of drug associated disorders in female prisoners were estimated to be 13 
times higher than in the general population [9].  
Addiction frequently co-occurs with other mental disorders in the general population [15,16]. 
The description of such comorbidities for prison populations had been identified as research 
necessity in a recent meta-analysis [17]. The priority is then to develop adequate treatments, 
which acknowledge the primary substance of addiction and comorbidities with other mental 
disorders, the so called ‘dual disorders’ [18]. Previous research has demonstrated, with 
respect to nicotine addiction of prisoners, that treatment was superior to mere forced 
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abstinence in smoke free jails, which by itself had hardly any affect on the addiction after 
release [19]. Most previous prison mental health studies have been conducted with samples 
from all existing prisoners with varying times spent in imprisonment. Research should assess 
addiction and comorbidities in newly received prisoners using structured clinical interviews to 
assess states of addiction prior to admission. At a later stage of imprisonment, reduced access 
to substances inside the penal justice systems may lead to negative scores on the standardized 
interview schedules resulting in missed diagnoses. Studies sampling from newly received 
prisoners will include mainly people with short-term and repeat sentences among them people 
with addiction. In contrast, studies of all existing inmates tend to include a larger proportion 
of long-term prisoners, for many of whom the addiction may not be the most relevant 
problem.  
Previous prison mental health studies from Germany recruited already existing prisoners at 
varying stages of imprisonment and they included all male or mixed gender samples with 
relatively small numbers of females [20,21]. The severity of traumatic experiences was 
significantly related with the prevalence of substance use disorders in a study from Germany 
[22]. The present study conducted in Berlin, Germany, aimed to assess the prevalence rates of 
substance use disorders and their comorbidities with other mental disorders in female 
prisoners newly committed to the penal justice system.  
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Methods 
This was a cross-sectional study of a sample of consecutively admitted female prisoners in 
Berlin, Germany.    
 
Sample 
The sample was recruited from the central prison admission facility for females, which serves 
the state of Berlin, Germany, an urban area with 3.5 million people, including the open, semi-
open and the closed systems. The facility does not serve women regarded to have reduced 
legal responsibility due to mental disorders in terms of §20 or §21 of the German Criminal 
Law. We aimed to recruit a total sample of 150 participants. The sample size was expected to 
yield percentage estimates with reasonable 95% confidence intervals (CI) for the total sample, 
i. e. 10% (95% CI: 5-15) or 20% (95% CI: 14-26). Prisoners with all types of verdict such as 
people in detention, remand prisoners and convicted prisoners were included in the study. The 
interview was usually scheduled within a week after imprisonment and always within the first 
month of imprisonment. Exclusion criteria for the study were the inability to communicate in 
German and a lack of capacity to provide informed consent. 
 
Measures 
Age, marital and employment status, educational and income level, were assessed on 
structured questions. The variables were dichotomized as living alone or with partner, 
education as low (comprising the categories 0-2 of the International Standard Classification of 
Education [ISCED] with all levels of education up to lower secondary levels of education) 
and high educational level (comprising the categories 3-6 of the ISCED with all educational 
levels from upper secondary level and higher [23]). Employment status was dichotomized to 
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employed (including people in training under the age of 28 years) and unemployed (including 
people in training of 28 years or older and retired people). This classification is in accordance 
with German legislation which requires the long term unemployed to take part in trainings to 
continuously qualify for social benefits [24]. The income level was dichotomized to €<990 
and €≥990 per month, which was the line of relative poverty for a single person household in 
2010 (http://www.diw.de/de/diw_01.c.411565.de/presse/diw_glossar/armut.html). The 
background of migration was assessed using an instrument developed by Schenk et al. [25]. 
The type of criminal offense was recorded.  
 
Mini International Neuropsychiatric Interview 
The fully structured Mini International Neuropsychiatric Interview (MINI) 6.0 [German 
version] was conducted to assess mental health and substance use disorders. The MINI was 
developed by Sheehan and Lecrubier [26] to categorize mental disorders according to the 
fourth version of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). The 
concordance between the MINI and longer interview schedules such as the Structured Clinical 
Interview for DSM-IV (SCID) is characterized by good or very good kappa values for most 
diagnoses [27].  The inter-rater reliability of the MINI is characterized by kappa coefficients 
above 0.75 for all diagnoses and 0.9 for the majority of the diagnoses [27]. The test-retest 
reliability introducing a second clinician for the rating was very good with kappa values 
above 0.75 for most diagnoses and below 0.40 for only one diagnosis (current mania) [27].  
 
Structured Clinical Interview for DSM-IV 
The MINI covers the antisocial personality disorders as only axis II diagnosis. Therefore, the 
interview schedule was supplemented by the module for borderline personality disorder 
(BPD) of the SCID [28]. The inter-rater reliability of the borderline module in the SCID-II 
was shown to have a kappa value of 0.78 [29]. The 1-3 week test-retest reliability of the 
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borderline module was shown to have a kappa value of 0.48 [30]. 
 
Fagerström Test of Nicotine Dependence 
Current smoking and the degree of nicotine dependence was assessed using the Fagerström 
Test of Nicotine Dependence FTND [31]. Reliability estimates for the FTND were 0.56 [32]. 
The FTND was shown to be a valid self-report measure among alcohol- and drug dependent 
individuals [33]. Scores of FTND≥6 were considered high degrees of nicotine dependence. 
 
Procedure 
The capacity to give informed consent was tested by assessing the potential participant’s 
ability to understand the purpose of the study. The field team consisted of two clinical 
psychologists trained and supervised by a senior consultant psychiatrist in using the 
instruments. The interviews lasted for 45-60 minutes and were held in a separate room of the 
prison to ensure confidentiality. The data were collected between April 2012 and May 2013. 
All interviewees provided written informed consent. The study was approved by the Ethics 
Board of the Charité Universitätsmedizin Berlin (EA1/302/11) and by the legal justice 
department of the State of Berlin, Germany (reference AL, 20.01.2012).  
 
Analyses 
Socio-demographic characteristics and prevalence rates of mental disorders were calculated as 
per cent values. For the prevalence rates, 95% Confidence Intervals (CI) using a bootstrap 
algorithm were computed. The mean and the standard deviation of the mean (SD) were 
calculated for the age. The statistical analyses were made using SPSS version 20.0. 
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Results 
Recruitment 
Figure 1 shows the flow of recruitment for the study. During the recruitment period, 338 
women entered the central facility for the admission of female prisoners to the penal justice 
system in Berlin. Of those, 278 women were screened for recruitment, 198 fulfilled the 
inclusion criteria and 150 agreed to participate in the survey. 
 
Place Figure 1 about here  
 
Socio-demographic characteristics of the sample 
The sample had a mean age of 34.3±10.8 years. Most of the female prisoners, n=139 (93%), 
were living alone; n=89 (59%) had low educational levels corresponding to ISCED 0-2; 
n=113 (75%) were unemployed; n=114 (76%) were living below the poverty line; n=124 
(83%) were non-migrants and 104 prisoners (69%) were mothers of children. The index 
crimes were sorted to the following offense categories: n=69 (46%) failure to pay a fine; n=35 
(23%) theft or fraud; n=16 (11%) remand prisoners under investigation; n=10 (7%) crimes 
related to drugs (possession or dealing); n=6 (4%) crimes related to immigration.  
 
Mental disorders in female prisoners with substance use disorders, with alcohol use 
disorders, with illicit drug use disorders and with opiate addiction 
Prevalence rates of mental and substance use disorders are shown in Table 1. Most prisoners, 
n=139, (91%; 95% CI: 85-95) had at least one mental disorder; n=97 (65%; 95% CI: 57-72) 
had at least one affective disorder; n=93 (62%; 95% CI: 54-70) had any one-year prevalence 
of substance use disorders without nicotine; n=31, (21%; 95% CI: 15-27) had alcohol 
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dependence and n=71 (47%; 95% CI: 39-55) illicit drug dependence. The most important 
illicit substances of addiction were opiates, marihuana, cocaine and amphetamines (see Table 
1). Anxiety disorders were prevalent in 65 prisoners (43%; 95% CI: 36-51); APD was 
prevalent in 41 prisoners (27%; 95% CI: 20-35) and BPD in 22 prisoners (15%; 95% CI: 9-
21). Low risk of suicide was present in n=63 (42%; 95% CI: 34-51), medium risk in n=5 (3%; 
95% CI: 1-6) and high risk in n=12 (8%; 95% CI: 4-13) of the sample.  
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Table 1: Prevalence rates of mental and substance use disorders in female prisoners  
 
 Total sample, N=150 
 Mental disorder N  % 95% CI 
≥ 1 disorder 136 91    85-95 
≥ 2 disorder 107 71 64-78 
Lifetime affective disorders 97 65 57-72 
Major depression 8 5 2-9 
Recurrent major depression  12 8 4-13 
Previous Major Depression 20 13 8-19 
Previous recurrent major depression 20 13 8-19 
Mania 0   
Previous mania 3 2   0-5 
Bipolar I disorder 13 8   5-13 
Previous bipolar I disorder 13 8 5-13 
Bipolar II disorder 2 1  0-3 
Previous bipolar II disorder 6 4 1-7 
Current affective disorder with psychotic features 1 1 0-2 
Lifetime affective disorders with psychotic 
symptoms 
8 5 2-9 
Substance use disorders without nicotine* 93 62   54-70 
Alcohol abuse/dependence 49 33 25-41 
Alcohol abuse 18 12  7-17 
Alcohol dependence 31 21  15-27 
Illicit drug abuse/dependence 76 51 43-59 
Illicit drug abuse 5 3  1-7 
Illicit drug dependence 71 47  39-55 
• Opiates 53 35 28-44 
o Heroine 41 27 20-35 
o Opiate substitution 19 13 8-20 
• Marihuana 28 19 13-26 
• Cocaine 25 17 11-23 
• Amphetamines 14 9 5-15 
• Hallucinogenics  3 2 0-4 
• Gamma-Hydroxybutyric acid 2 1 0-3 
Current Smoking 121 81 75-87 
Nicotine Dependence (FTND: 6-10 points) 62 41 33-50 
Anxiety Disorders 65 43 36-51 
Current panic disorder 7 5  1-8 
Lifetime panic disorder 25 21 15-28 
Agoraphobia 18 12 7-17 
Social anxiety disorder 7 5  1-8 
Generalised anxiety disorder 3 2   0-5 
Obsessive compulsive disorder 11 7   3-11 
Posttraumatic stress disorder 39 26 19-33 
Current psychotic disorder 3 2 0-5 
Lifetime psychotic disorder 8 5   2-9 
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Anorexia nervosa 4 3   1-5 
Bulimia nervosa 0   
Personality disorder (BPD/ASPD) 53 35    28-43 
Antisocial personality disorder 41 27    20-38 
Borderline personality disorder 22 15    9-21 
Risk of Suicide    
• None 70 47  38-55 
• Low 63 42  34-51 
• Medium 5 3  1-6 
• High 12 8  4-13 
 
*one year prevalence rates; BPD=borderline personality disorder; APD=antisocial personality disorder 
 
Comorbidities of mental health and substance use disorders are shown in Table 2. Ninety per 
cent of the people with addiction had at least one other mental disorder. Addiction co-
occurred with affective disorders in n=63 (68%), with anxiety disorders in n=41 (44%), with 
personality disorders in n=44 (47%) and with suicidal ideation in n=54 (58%). People with 
different types of addiction, such as alcohol use disorders, illicit drug use disorders and 
among them the subgroup with opiate addiction had comorbidities with a range of different 
psychiatric disorders. There was no specific pattern of comorbidities associated with addiction 
or any of the different types of addiction.   
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Table 2: Substance use disorders and their comorbidities in female prisoners. Patterns of comorbidities are shown for subgroups of prisoners with 
alcohol use, drug use and opiate use disorders.  
 
 
 Substance use 
disorders (without 
nicotine) N=93 
Alcohol use disorders 
N=57 
Illicit drug use 
disorders N=76 
Opiate use disorders 
N=53 
 Mental disorder N %  N %  N %  N %  
≥ 2 disorder 84 90 45 92 71 93 49 93 
Lifetime affective disorders 63 68 34 69 52 68 34 64 
Major depression 3 3 0  3 4 2 4 
Recurrent major depression  9 10 5 10 8 11 7 13 
Previous Major Depression 10 11 4 8 9 12 8 15 
Previous recurrent major depression 15 16 7 14 13 17 9 17 
Mania 0  0  0  0  
Previous mania 2 2 1 2 2 3 2 4 
Bipolar I disorder 11 12 8 16 8 11 3 6 
Previous bipolar I disorder 9 10 6 12 7 9 2 4 
Bipolar II disorder 1 1 1 2 0  0  
Previous bipolar II disorder 3 3 2 4 2 3 1 2 
Current affective disorder with psychotic features 1 1 1 2 0  0  
Lifetime affective disorders with psychotic symptoms 6 6 4 8 4 5 3 6 
Alcohol abuse/dependence 49 53   32 42 19 36 
Alcohol abuse 18 19 18 37 12 16 5 9 
Alcohol dependence 31 33 31 63 20 26 14 26 
Illicit drug abuse/dependence 76 82 32 65     
Illicit drug abuse 5 5 3 6 5 7 1 2 
Illicit drug dependence 71 76 29 59 71 93 52 98 
• Opiates 53 57 19 39 53 70   
o Heroine 41 44 12 24 41 54 41 77 
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o Opiate substitution 19 20 9 18 19 25 19 36 
• Marihuana 28 30 14 29 26 34 17 32 
• Cocaine 25 27 12 24 25 33 20 38 
• Amphetamines 14 15 9 18 14 18 8 15 
• Hallucinogenics  3 3 2 4 3 4 0  
• Gamma-Hydroxybutyric acid 2 2 2 4 2 3 1 2 
Current Smoking 86 92 45 92 70 92 53 100 
Nicotine Dependence (FTND: 6-10 points) 46 49 27 55 35 46 27 51 
Anxiety Disorders 41 44 23 47 32 42 21 40 
Current panic disorder 5 5 3 6 4 5 3 6 
Lifetime panic disorder 19 20 7 14 12 16 10 19 
Agoraphobia 12 13 9 18 6 8 5 9 
Social anxiety disorder 6 7 5 10 4 5 2 4 
Generalised anxiety disorder 2 2 2 4 1 1 1 2 
Obsessive compulsive disorder 7 8 5 10 6 8 4 8 
Posttraumatic stress disorder 26 28 15 31 23 30 15 28 
Current psychotic disorder 0  0  0  0  
Lifetime psychotic disorder 7 8 5 10 6 8 5 9 
Anorexia nervosa 3 3 2 4 2 3 2 4 
Bulimia nervosa 0  0  0  0  
Personality disorder (BPD/ASPD) 44 47 18 37 37 49 27 51 
Antisocial personality disorder 35 38 18 37 29 38 24 45 
Borderline personality disorder 16 17 11 24 13 17 7 13 
Risk of Suicide         
• None 39 42 21 43 33 43 24 45 
• Low 42 45 24 49 32 42 22 42 
• Medium 2 2 1 2 1 1 1 2 
• High 10 11 3 6 10 13 6 11 
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Discussion 
Main results 
About two thirds of the consecutively admitted female prisoners had substance use disorders, 
mainly associated with opiates. Of the prisoners with addiction, 90% had at least one other 
mental disorder. Different types of addiction frequently co-occurred with affective, personality 
and anxiety disorders.  
 
Strengths and limitations 
This is the first study that systematically explores the comorbidity of substance use disorders 
and mental disorders in female prisoners at admission to the penal justice system. The study 
recruited consecutively admitted women so that the sample included newly received female 
prisoners regardless of their length or type of verdict. Independent researchers established 
diagnoses using standardised instruments.  
The study also has several limitations. Firstly, the recruitment was carried out in one site 
responsible for all admissions of female prisoners in one German metropolitan area and it 
remains unclear as to what degree the findings can be generalised to other regions in Germany 
or internationally to other legal, social and cultural contexts. Secondly, the sample did not 
include non-German speaking prisoners, and the prevalence of both addiction disorders and 
other comorbid mental disorders may be different in migrants.  
 
Comparison against the literature 
The prevalence rates of mental health and substance use disorders found in our study are much 
higher than in the female general population in Germany [34]. This is inline with most previous 
prison research [9]. Whereas the rates of serious mental illnesses were within the expected 
range from previous prison studies [17], the rate of alcohol addiction was even higher than 
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expected from the literature [9].  
Most previous prison mental health studies used sampling designs including all existing 
inmates. Those studies recruited largely longer-term prisoners as compared to studies sampling 
from all admissions to a system. In samples of all existing prisoners at least part of the sample 
is under forced abstinence when assessment takes place. They may therefore be less 
meaningful to assess addictions and comorbidities. The most comparable study to ours reported 
prevalence rates of female prisoners in the US [35]. It used the same diagnostic instrument and 
same sampling strategy [35]. Surprisingly similar rates were found for current major depression 
(14% US vs. 13% present), PTSD (23% US vs. 26% present), substance use disorders (68% US 
vs. 62% present) and APD (27% US vs. 27% present), whereas even higher rates were reported 
for current bipolar disorder (25% US vs. 10% present). Given that our study showed very 
similar prevalence rates of mental health and substance use disorders in the total sample 
compared to the study conducted in the US, the comorbidities reported in this study may be 
generalizable to wider contexts including the US. Female prisoners with substance use 
disorders and several subgroups with specific addictions (to alcohol, drugs and opiates) very 
commonly also had affective, personality and anxiety disorders without any specific patterns of 
comorbidities. The rates of comorbid anxiety disorders or depression in female prisoners with 
opiate addiction were higher than the rates of those comorbidities reported for people with 
opiate addiction in community addiction treatments [36]. The findings indicate that the 
development of adequate interventions for prisoners has to consider addiction commonly co-
occurring with a range of comorbidities. Any pure addiction focus or focusing on a specific 
dual disorder may not be sufficient to plan the provision of adequate services.  
 
Implications for research, politics and health service development 
Prevalence rates of mental health and substance use disorders of prison populations could be 
more similar across different international contexts than previously thought, if studies using the 
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same structured interview and the same sampling strategy were compared. Effective 
interventions need likely to be non-specific with respect to the disorder, generic, robust and 
flexible. They need to contain elements to sustain abstinence beyond imprisonment but also 
need to allow for comorbidities of a range of other mental health conditions. Interventions not 
focussing on pathologies or deficits at all, such as resource-oriented therapies could be a 
promising option for future developments [37].  
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